Related Experiment Video
Updated: Feb 6, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Chemoembolization in Conjunction with Bevacizumab: Preliminary Results
Giammaria Fiorentini1, Donatella Sarti1, Camillo Aliberti2
1Department of Oncology-Hematology, Azienda Ospedaliera "Ospedali Riuniti Marche Nord," San Salvatore Hospital, Via Lombroso 1, Pesaro 61122, Italy.
Abstract:
Transarterial chemoembolization is an effective, minimally invasive therapy that is widely used for treatment of unresectable colorectal cancer liver metastases (CRC-LM). However, chemoembolization induces a hypoxic microenvironment, which increases neoangiogenesis and may promote early progression. For this reason, transarterial chemoembolization efficacy may be improved by combining it with an angiogenesis inhibitor, such as bevacizumab. This report shows that transarterial chemoembolization with irinotecan-loaded polyethylene glycol embolics and bevacizumab therapy was effective and well tolerated by 6 patients with CRC-LM, resulting in a disease control rate of 83% and an overall improvement in quality of life.
Related Concept Videos
Cross-Sectional Research
Ionic Bonding and Electron Transfer
The Eukaryotic Promoter Region

